Information Provided By: 
Fly News Breaks for May 4, 2017
GMED
May 4, 2017 | 07:19 EDT
As reported previously, Canaccord analyst Kyle Rose upgraded Globus Medical to Buy from Hold on improving fundamentals and the company reaching an inflection point in its core business. The analyst said he sees upside to guidance weighted to the second half of the year as the U.S. business stabilizes, management executes, and regulatory clearances for emerging technologies progress. Rose raised his price target to $37 from $30 on Globus Medical shares.
News For GMED From the Last 2 Days
There are no results for your query GMED
